EVISA Print | Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).

Supporters of EVISA includes:

Copper molecule shows promise in fighting against cancer


Cisplatin has been used as a chemotherapy agent for cancer for over 30 years. While the drug is effective against certain cancers - such as lung cancer and testicular cancer - it does neither work for all cancers nor for all patients.
Also, cisplatin is not without side effects - it often causes nausea, vomiting and diarrhea and is toxic to kidneys and ears. Another complication of cisplatin is that of drug resistance - a problem that often emerges with drugs that have been widely used for a long time.

The new candidate drug for chemotherapy:
The serious side effects of cisplatin where the motivation for the researchers, led by Thorsten Glaser, professor in inorganic chemistry at the University of Bielefeld to design a new molecule, says Glaser and continues that his group "wanted an agent that would treat cancers that have become immune to cisplatin though its use in earlier treatments".

The new copper-containing molecule attacks the DNA of cancer cells but in contrast to cisplatin does not bind with the nucleobases of DNA but binds to the phosphate of the DNA. The team designed the molecule by integrating two copper atoms that preferentially bind with phosphates on the DNA - like a key that fits uniquely inside a lock. This binding interferes with the cellular processes of the cancer cell so it cannot replicate itself, and it eventually dies.

The new agent containing two copper atoms (above) ‘docks’ precisely with the DNA molecule (below) of a cancer cell and stops it from growing. As a result, the cancer cell dies. Credit: Bielefeld University

The copper ions sit at two points protruding from the molecule - like a horseshoe presenting its two ends (see the figure). The distance between the two points of the "horseshoe" is exactly the same as the distance between the phosphates in the DNA, so the molecule docks snugly onto the DNA. "Because two phosphates bind simultaneously, the binding strength is greater and that increases the efficacy," says Prof. Glaser.

The scientists have developed a procedure for manufacturing the new molecule and also demonstrated the activity to prevent cancer cells from spreading. The result was that "the copper complex is more effective than cisplatin," says Glaser. "The highest number of cancer cells died at a concentration of 10 micromolar. With cisplatin, you need 20 micromolar."

However, he also cautions that while the results in the lab show promise, their work is basic research: "How and whether the copper complex will actually be given to cancer patients is something that medical research will have to determine in the years to come."

When carrying out the research on the new agent, Professor Glaser and his team cooperated with the research teams of Professor Dr. Dario Anselmetti (Biophysics and nanoscience) and Professor Dr. Gabriele Fischer von Mollard (Biochemistry) -- both also at Bielefeld University. Dario Anselmetti's colleagues used atomic force microscopy to produce the images confirming that the copper complex binds with the DNA. Gabriele Fischer von Mollard's team tested how the cancer cell culture responded to the agent.

The above story is based on materials provided by the University of Bielefeld.

The cited study:

Thomas Jany, Alexander Moreth, Claudia Gruschka, Andy Sischka, Andre Spiering, Mareike Dieding, Ying Wang, Susan Haji Samo, Anja Stammler, Hartmut Bögge, Gabriele Fischer von Mollard, Dario Anselmetti, Thorsten Glaser, Rational Design of a Cytotoxic Dinuclear Cu2Complex That Binds by Molecular Recognition at Two Neighboring Phosphates of the DNA Backbone, Inorg. Chem., 2015;  DOI: 10.1021/ic5028465

Related EVISA Resources

Brief summary: Speciation analysis for the study of metallodrugs and their biomolecular interactions
Brief summary: Chemical speciation analysis for the life sciences
Link database: Toxicity of platinum compounds
Glossary: Metallodrugs
Journal Database: Journals related to Medicinal Chemistry

Journal Database: Journals related to Pharmacology and  Pharmacy
Journal Database: Journals related to Oncology
Journal Database: Journals related to Metallomics
Link Database: Research groups working on metallodrugs
Directory of scientists: Researchers working on metallodrugs
Link page: All about Pharmacy and Pharmaceutical Sciences

Related EVISA News

October 29, 2014: Side effects of cisplatin chemotherpy: Platinum speciation matters
October 14, 2013: Speciation analysis for cancer diagnosis
Januray 10, 2007: Dartmouth researchers find that arsenic triggers unique mechanism in rare leukemia

last time modified: March 4, 2015


Imprint     Disclaimer

© 2003 - 2024 by European Virtual Institute for Speciation Analysis ( EVISA )